HIV-infected individuals that participated in the GRACE study, conducted from October 2006-December 2008, received antiviral therapy based on a darunavir/ritonavir drug cocktail. More than half of the trial participants completed a survey between 2010-2011 to evaluate their experiences, opinions, and outcomes. The survey showed that 76% of the respondents felt that the GRACE trial made them feel differently about their health/HIV care, 82% became more focused on their health, and 87% continued treatment after GRACE.
Access to treatment was reported as the most positive factor in patient enrollment, according to authors Kathleen Squires and colleagues from Jefferson Medical College of Thomas Jefferson University (Philadelphia, PA), University of Cincinnati College of Medicine (OH), The Well Project, Inc. (Nellysford, VA), University of California, Los Angeles, Janssen Research & Development, and Janssen Services (Titusville, NJ).
Factors associated with difficulties in adherence to HIV medications, a critical part of maintaining healthy lives, included being the primary caregiver for children, unemployment, and transportation difficulties. These findings were reported in the article “Insights on GRACE (Gender, Race, and Clinical Experience) from the Patient’s Perspective: GRACE Participant Survey.”
“Identification of patients at high risk for suboptimal clinical trial outcomes through surveys such as these should help improve HIV medication compliance and retention,” says Editor-in-Chief Jeffrey Laurence, MD, Director of the Laboratory for AIDS Virus Research at Weill Medical College of Cornell University, New York, NY.
About the Journal
AIDS Patient Care and STDs is the leading journal for clinicians, enabling them to keep pace with the latest developments in this evolving field. Published monthly in print and online, the Journal spans the full spectrum of adult and pediatric HIV disease, diagnosis, treatment, prevention, and education. Tables of content and a sample issue may be viewed on the AIDS Patient Care and STDs website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including AIDS Research and Human Retroviruses, Viral Immunology, and Journal of Palliative Medicine. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals and books is available on the Mary Ann Liebert, Inc., publishers website.